Kronos Bio, Inc. (KRON)
0.8800
+0.0129 (1.49%)
Inactive Ā· Last trade price on Jun 20, 2025
Kronos Bio Employees
Kronos Bio had 10 employees as of December 31, 2024. The number of employees decreased by 53 or 84.13% compared to the previous year.
Employees
10
Change (1Y)
-53
Growth (1Y)
-84.13%
Revenue / Employee
$919,200
Profits / Employee
-$6,448,500
Market Cap
n/a
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 10 | -53 | -84.13% | 10 | 0 |
| Dec 31, 2023 | 63 | -34 | -35.05% | 62 | 1 |
| Dec 31, 2022 | 97 | 1 | 1.04% | 97 | 0 |
| Dec 31, 2021 | 96 | 33 | 52.38% | 96 | 0 |
| Dec 31, 2020 | 63 | - | - | 63 | 0 |
KRON News
- 1 year ago - Kronos Bio Completes Sale to Concentra Biosciences - Market Watch
- 1 year ago - KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON - Business Wire
- 1 year ago - Kronos Bio Enters into Agreement to Be Acquired by Concentra BiosciencesĀ for $0.57 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 1 year ago - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 2 years ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 2 years ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 2 years ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire